Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib plus bortezomib in acute myeloid leukemia
2007-000273-35Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Apr 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib and bortezomib in acute myeloid leukemia (AML) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Safety and tolerability in Part A and Effect of tipifarnib plus defined-dose bortezomib in Part B. Started Apr 2007; status: completed.
02
Drugs
tipifarnibbortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-000273-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000273-35.